Ashton Lane

Stockdales of Sale at Ashton Lane is a small, welcoming care home supporting up to five adults with physical disabilities, sensory impairments, and learning disabilities. The recent inspection highlights a warm, person-centered environment where residents enjoy active lives, a clean and modern setting, and dedicated support from well-trained staff. Families praise the home for its kind atmosphere and strong community engagement, though inspectors noted certain administrative and management oversight areas requiring attention.

When it comes to safety, the home maintains clean premises, safe staffing levels, and effective safeguarding practices to protect residents from harm. However, inspectors identified shortcomings in medicines management, including inaccurate medication records, missing guidance for variable-dose drugs, and incomplete records for thickening powders used for residents with swallowing difficulties.

The care provided is effective, featuring thorough pre-admission assessments, a strong commitment to staff development, and close collaboration with external healthcare professionals. Staff understand and apply the principles of the Mental Capacity Act, ensuring that residents are supported to make choices in their best interests through proper legal frameworks.

Residents experience a caring and compassionate environment where staff treat them with genuine warmth, respect, and dignity. Staff take the time to build strong rapport and understand individual communication styles, ensuring that residents feel valued and involved in daily life.

The service is highly responsive to individual needs, offering personalised care plans and excellent support for hobbies, social activities, and access to the local community. Non-verbal communication needs are met through visual cues and picture cards, and relatives feel fully involved and able to raise any concerns easily.

Management and leadership show a strong commitment to a positive, person-centered culture and staff support. Nevertheless, leadership fell short in governance oversight, as evidenced by missed notifications to regulators and gaps in medicines record-keeping that led to a breach of regulations.